We have developed a sonophoresis-powered SMARTPATCH drug

delivery platform - a needle and cannula-free, wearable technology that harnesses the power of ultrasound to provide a safe, controlled, and painless method for delivering large molecule medicines, starting initially on insulin.

Building upon seven years research, the platform utilises ground-breaking sonophoresis ultrasound technology to naturally enlarge skin pores, facilitating the painless administration of medications. Whilst many organisations have looked at transdermal sonophoresis drug delivery, we are the only company that has managed to create a miniaturized sonophoresis device, small enough to be wearable and suitable to deliver several large molecules with rapid adaptation.

We demonstrated feasibility to TRL5 (proven safe and effective delivery of insulin in vivo), won over 50 European innovation awards, and secured high-profile Pharma/Medtech partners as Merck, pilots with different stakeholders and their molecules of interest, and LOIs from BIOTON or LTS Lohmann stating their interest to validate the technology on human trials.